期刊
ALZHEIMERS & DEMENTIA
卷 8, 期 4, 页码 337-342出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2012.04.007
关键词
Alzheimer's disease; Neuroimaging; Biomarkers
资金
- National Institute on Aging of the National Institutes of Health [U01-AG024904]
- Alzheimer's Association
- PharmaCog from the European Commission's Innovative Medicine Initiative [115009]
- grant Programma Strategico [RF07.39.2]
- grant Programma Strategico 2007, conv. PS39 [RF07.39.2]
The Alzheimer's Disease Neuroimaging Initiative (ADNI) was launched in 2003 to speed drug development by validating imaging and blood/cerebrospinal fluid biomarkers for Alzheimer's disease clinical treatment trials. ADNI is a naturalistic (nontreatment) multisite longitudinal study. A true public private partnership, the first phase of ADNI (ADNI 1) set a new standard for data sharing without embargo. In addition, it has been extended to 2017 by additional funding (North American-ADNI Grand Opportunities and ADNI 2) as well as multiple projects around the world, collectively known as Worldwide ADNI (WW-ADNI). The goal of WW-ADNI is to harmonize projects and results across different geographical sites and to encourage and harmonize data management and availability to investigators around the world. WW-ADNI projects are currently underway in North America, Europe, Japan, Australia, Korea, Taiwan, and Argentina, with a nascent program in China and a possible future program in Brazil. (C) 2012 The Alzheimer's Association. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据